Tag: LLC

Finance

Investors Alert : Pike (NYSE:PIKE), Huntington Bancshares Incorporated (NASDAQ:HBAN), Vanguard Natural (NASDAQ:VNR), WellPoint Inc. (NYSE:WLP), Heidrick & Struggles (NASDAQ:HSII)

Pike Corporation (NYSE:PIKE) announced that it has signed a definitive merger agreement under which investment firm Court Square Capital Partners in partnership with J. Eric Pike, the Company’s Chairman and Chief Executive Officer, will acquire the Company in a transaction in which each of the Company’s shareholders will receive $12.00 in cash, without interest and less any applicable withholding taxes, for each share of the … Continue reading Investors Alert : Pike (NYSE:PIKE), Huntington Bancshares Incorporated (NASDAQ:HBAN), Vanguard Natural (NASDAQ:VNR), WellPoint Inc. (NYSE:WLP), Heidrick & Struggles (NASDAQ:HSII)

John Bellich
Finance

Eye Catching Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Informatica (NASDAQ:INFA), Canadian Pacific Railway Limited (NYSE:CP), EnLink Midstream, LLC (NYSE:ENLC), Trex (NYSE:TREX)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. Currently there are 5 analysts that rate ARIAD Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)’s stock on 31 July traded at beginning with a price of $6.03 and when day-trade ended the stock … Continue reading Eye Catching Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Informatica (NASDAQ:INFA), Canadian Pacific Railway Limited (NYSE:CP), EnLink Midstream, LLC (NYSE:ENLC), Trex (NYSE:TREX)

John Meady
Finance

Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Akebia Therapeutics Inc. (NASDAQ:AKBA) offered 5.9 million shares in its Thursday IPO at $17 a share, the high end of the stock’s expected price range. Among other therapeutics, the biopharma company is developing a once-daily oral therapy for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock performance was -0.99% in last session and finished the day at $20.00. Traded volume was 219,904 million shares … Continue reading Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Kevin Long